Saltar al contenido
Merck

N6037

Sigma-Aldrich

Neridronate

≥97% (NMR), solid, bone resorption inhibitor

Sinónimos:

6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C6H17NO7P2
Número de CAS:
Peso molecular:
277.15
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77

product name

Neridronate, ≥97% (NMR), solid

description

may contain <1% (w/w) inorganic salts

Quality Level

assay

≥97% (NMR)

form

solid

color

white

solubility

H2O: >5 mg/mL

storage temp.

2-8°C

SMILES string

NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)

InChI key

PUUSSSIBPPTKTP-UHFFFAOYSA-N

Biochem/physiol Actions

Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Evelina Maines et al.
Journal of bone and mineral metabolism, 30(4), 434-438 (2011-11-09)
Over recent years, several reports have been published on unusual cases of osteonecrosis of the jaw (ONJ) in adults using second- and third-generation nitrogen-containing bisphosphonates such as pamidronate, alendronate, risedronate and zoledronate, but no case has ever been reported either
Daniela Merlotti et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 26(3), 512-518 (2010-09-04)
Aminobisphosphonates actually represent the most common treatment for Paget disease of bone (PDB). In a previous study we demonstrated that either zoledronic acid (4 mg) or neridronate (200 mg) given as a single intravenous infusion showed a similar short-term efficacy
Filippo Graziani et al.
Journal of clinical periodontology, 36(5), 419-427 (2009-05-08)
To determine if the adjunctive use of intra-muscular neridronate (NE) during non-surgical periodontal treatment (PT) provides, in patients with generalized chronic periodontitis (GCP), adjunctive benefits as compared with PT alone 3 months after the completion of a 3-month NE therapy.
Massimo Varenna et al.
Rheumatology (Oxford, England), 52(3), 534-542 (2012-12-04)
Complex regional pain syndrome type I (CRPS-I) is a severely disabling pain syndrome for which no definite treatment has been established. The aim of this multi-centre, randomized, double-blind placebo-controlled trial was to test the efficacy of the amino-bisphosphonate neridronate in
Aino-Liisa Saari et al.
Molecules (Basel, Switzerland), 17(9), 10928-10945 (2012-09-14)
Aminobisphosphonates, e.g., alendronate and neridronate, are a well known class of molecules used as drugs for various bone diseases. Although these molecules have been available for decades, a detailed understanding of their most important physicochemical properties under comparable conditions is

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico